Please assess the completion status of the following clinical trial:

Trial Title: Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants and children 6-23 months of age at enrollment as determined by medical history, physical examination and clinical judgment of the investigator~* Birth weight ≥ 2500 g~* ≥ 37 weeks of pregnancy or judge to be full-term by the midwife or birth attendant~* Parents aged 18 years and above and legal guardians aged 21 years and above as per the legal authorization in the Philippines, who have voluntarily given informed consent~* Parents/ legal guardians willing to follow the study procedures of the study and available for the entire duration of the study~Exclusion Criteria:~* Child with a congenital abnormality~* Subject with abnormal routine biological values at screening~* Subject concomitantly enrolled or scheduled to be enrolled in another trial~* Acute illness, in particular infectious disease or fever (axillary temperature ≥37.5°C), within three days prior to enrolment and vaccination~* Known history of immune function disorders including immunodeficiency diseases, or chronic use of systemic steroids (\>20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs~* Child with a previously ascertained or suspected disease caused by S. typhi~* Child who have had household contact with/and or intimate exposure to an individual with laboratory-confirmed S. typhi~* Known history or allergy to vaccines or other medications~* Know history of allergy to eggs, chicken protein, neomycin and formaldehyde~* History of uncontrolled coagulopathy or blood disorders~* Mother has known HIV infection or other immune function disorders~* Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the subject and interfere with the assessment of the study objectives~* Child whose parents or legal guardian planning to move from the study area before the end of study period

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- A (Single dose) (Type: EXPERIMENTAL): One dose of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly at first dost (Day 0).~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Week 24).~One booster dose of Vi-DT 0.5 mL is administrated 2 years apart (Week 96). MMR for age group at 9-12 months.
- B (Two dose) (Type: ACTIVE_COMPARATOR): Two doses of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly 6 months apart (Day 0 and Day 168 (Week 24)).~MMR for age group at 9-12 months.
- C (Placebo/Comparator) (Type: PLACEBO_COMPARATOR): One dose of Placebo (0.9% sodium chloride isotonic solution) 0.5 mL is administrated intramuscularly at first dost (Day 0).~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Day 168; Week 24).~MMR for age group at 9-12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete